2022 Revenues ($USD) : $276,984,000
2022 R&D spend : $51,018,000
2022 Number of Employees : 800
Fiscal Year End : 12/31/2021
Company CEO : William Hoffman, CEO

Focused on developing devices for venous thromboembolism and patients with venous diseases, Inari Medical has developed FDA-cleared minimally-invasive, catheter-based mechanical thrombectomy devices that can pull clots out of large vessels and eliminate the need for thrombolytic drugs. The company priced an underwritten public offering worth up to $186.3 million in March 2022. The company was founded in 2011, gathering $44.1 million in total funding to date. In August 2022, the company announced that it would promote its COO Drew Hykes to succeed Bill Hoffman as the company’s CEO. Hykes will formally assume the CEO mantle in January 2023. Hykes began working at Inari in 2017 as chief commercial officer and was promoted to COO in 2020. –BB